FindTrial
Sign In

TO STUDY THE EFFECT OF A DRUG (SAROGLITAZAR) USED TO TREAT DYSLIPIDEMIA ON THE RISK MARKERS OF HEART DISEASE

TO STUDY THE EFFECT OF SAROGLITAZAR ON ââ?¬Ë?NON-TRADITIONALââ?¬â?¢ CV RISK MARKERS IN PATIENTS WITH DYSLIPIDEMIA

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2022/09/046049
Enrollment
96
Registered
2022-09-29
Start date
Unknown
Completion date
Unknown
Last updated
2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E785- Hyperlipidemia, unspecified

Interventions

Intervention1: Saroglitazar: 4 mg tablet once a day for 24 weeks Control Intervention1: Fenofibrate: 160 mg once a day for 24 weeks

Sponsors

Dayanand Medical college and Hospital
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Dyslipidemia not controlled with statins for at least 3 months

Exclusion criteria

Exclusion criteria: 1. Significant alcohol intake ( > 140 g/week in females and > 210 g/week in males) 2. Uncontrolled thyroid disease 3. Active cardio-pulmonary disease. 4. Current/past history of malignancy. 5. Chronic liver disease, viral hepatitis or chronic kidney disease (CKD).

Design outcomes

Primary

MeasureTime frame
To study the effect of saroglitazar on hsCRP in patients with dyslipidemia not controlled with statinsTimepoint: 24 weeks—

Secondary

MeasureTime frame
1. To study the effect of saroglitazar on other non-traditional cardiovascular risk markers in patients with dyslipidemia not controlled with statins 2. To study the effect of saroglitazar on lipid profile and transaminases in patients with dyslipidemia not controlled with statins.Timepoint: 24 weeks—

Countries

India

Contacts

Public ContactDr Omesh Goyal

Dayanand Medical College and Hospital

goyalomesh@yahoo.co.in9914821155

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026